Truist Financial Corp Checkpoint Therapeutics, Inc. Transaction History

Truist Financial Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$2.68 - $4.46 $565 - $941	-211 Reduced 1.49%	13,958 $43,000
Q3 2021 Nov 05, 2021	BUY	$2.5 - $3.53 $8,012 - $11,313	3,205 Added 29.23%	14,169 $47,000
Q1 2021 May 17, 2021	BUY	$2.6 - $4.16 $442 - $707	170 Added 1.57%	10,964 $34,000
Q4 2020 Nov 19, 2021	SELL	$2.19 - $2.96 $7,154 - $9,670	-3,267 Reduced 23.23%	10,794 $29,000
Q4 2020 Feb 18, 2021	BUY	$2.19 - $2.96 $8,893 - $12,020	4,061 Added 40.61%	14,061 $38,000
Q4 2019 Feb 14, 2020	BUY	$1.18 - $2.39 $11,800 - $23,900	10,000 New	10,000 $17,000

1.91M

Ticker CKPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,497,000
Market Cap $281M
Description
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to...

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Truist Financial Corp with notifications on news.